Polymyalgia rheumatica: Clinical picture and principles of treatment

Polskie Archiwum Medycyny Wewnetrznej

Volumn 118, Issue 6, 2008, Pages 377-380

  Zimmermann Górska, Irena ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Giant cell arteritis; Polymyalgia rheumatica

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; C REACTIVE PROTEIN; CALCIUM; CORTICOSTEROID; INFLIXIMAB; METHOTREXATE; PREDNISOLONE; STEROID; VITAMIN D;

COMORBIDITY; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; ERYTHROCYTE SEDIMENTATION RATE; FROZEN SHOULDER; GIANT CELL ARTERITIS; HUMAN; JOINT STIFFNESS; NECK PAIN; REVIEW; RHEUMATIC POLYMYALGIA; STEROID THERAPY; UNSPECIFIED SIDE EFFECT;

EID: 46949098178     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.422     Document Type: Review

References (39)

1. Nothnagl T, Leeb BF. Diagnosis, differential diagnosis and treatment of polymyalgia rheumatica. Drugs Aging. 2006; 5: 391-402.
2. Barber HS. Myalgic syndrome with constitutional effects: polymyalgia rheumatica. Ann Rheum Dis. 1957; 16: 230-237.
3. Paulley JW, Hughes JP. Giant cell arteritis or arthritis of the aged. BMJ. 1960; 2: 1562-1567.
4. Nuti R, Giordano N, Martini G, et al. Is polymyalgia rheumatica caused by infectious agents? J Rheumatol. 2005; 32: 200-201.
5. Wagner AD, Gerard HC, Fresemann T, et al. Detection of Chlamydia pneumoniae in giant cell vasculitis and correlation with the topographic arrangement of tissue-infiltrating dendritic cells. Arthritis Rheum. 2000; 43: 1543-1551.
6. Martinez-Tabod VM, Bartolome MJ, Lopez-Hoyos M, et al. HLA-DRB1 allele distribution in polymyalgia rheumatica and giant cell arteritis: influence on clinical sub-groups and prognosis. Semin Arthritis Rheum. 2004; 34: 454-464.
7. Salvarani C, Macchioni P, Zizzi F, et al. Epidemiologic and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in northern Italy. Arthritis Rheum. 1991; 34: 351-356.
8. Weyand CM, Goronzy JJ. Arterial wall injury in giant cell arteritis. Arthritis Rheum. 1999; 42: 844-853.
9. Cutolo M, Montecucco CM, Cavagna L, et al. Serum cytokines and steroidal hormones in polymyalgia rheumatica and elderly-onset rheumatoid arthritis. Ann Rheum Dis. 2006; 65: 1438-1443.
10. Hernández-Rodriguez J, Segarra M, Vilardell C, et al. Tissue production of pro-inflammatory cytokines (IL-1 beta, TNF alpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology (Oxford). 2004; 43: 294-301.
11. Weyand CM, Hicok KC, Hunder GG, et al. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med. 1994; 121: 484-491.
12. Narvaez J, Bernad B, Diaz-Torne C, et al. Low serum levels of DHEAS in untreated polymyalgia rheumatica/giant cell arteritis. J Rheumatol. 2006; 33: 1293-1298.
13. Hellmann DB, Hunder GG. Giant cell arteritis and polymyalgia rheumatica. In: Harris ED, Budd RC, Firestein GS, et al., eds. Kelley's Textbook of Rheumatology, Elsevier Saunders, 2005; 7th ed, 1343-1356.
14. Chatelain D, Duhaut P, Bosshard S, et al. Isolated peripheral small-vessel vasculitis on temporal artery biopsy specimen: new diagnostic criterion for polymyalgia rheumatica? The GRACG study. Ann Rheum Dis 2007; 66 (Suppl. II): 77.
15. Hazleman BL. Polymyalgia rheumatica and giant cell arteritis. In: Klippel JH, Dieppe PA, eds. Rheumatology. 2nd ed, Mosby, 7/21.1./7.21.8.
16. Salvarani C, Cantini F, Boiardi L, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med. 2002; 347: 261-271.
17. Myklebust G, Gran IT. A prospective study of 287 patients with polymyalgia rheumatica and temporal arteritis: clinical and laboratory manifestations at onset of disease and at time of diagnosis. Br J Rheumatol. 1996; 35: 1161-1168.
18. Singleton JD. Polymyalgia rheumatica. In: Rheumatology secrets, West S, ed. Hanley and Belfus. 2nd ed., 2002; 195-199.
19. Frediani B, Falsetti P, Storri L, et al. Evidence for synovitis in active polymyalgia rheumatica: sonographic study in a large series of patients. J Rheumatol. 2002; 29: 123-130.
20. Healey LA. Long-term follow-up of polymyalgia rheumatica: evidence of synovitis. Semin Arthritis Rheum. 1984; 13: 322.
21. Mertens JCC, Willemsen G, van Saase JLCM, et al. Polymyalgia rheumatica and temporal arteritis: a retrospective study of 111 patients. Clin Rheumatol. 1995: 14: 650-655.
22. Haga HJ, Eide GE, Brun J, et al. Cancer in association with polymyalgia rheumatica and temporal arteritis. J Rheumatol 1993; 20: 1335-1339.
23. Myklebust G, Wilsgaard T, Jacobsen BK, et al. No increased frequency of malignant neoplasms in polymyalgia and temporal arteritis. A prospective longitudinal study of 398 cases and matched population controls (abstract 1678). Arthritis Rheum. 2001; 44: S332.
24. Kuttikat A, Keat A, Hughes R, et al. A case of polymyalgia rheumatica, microscopic polyangitis, and B-cell lymphoma. Nature Clin Practice Rheumatology. 2006; 12: 686-690.
25. Naschitz JE, Slobodin G, Yeshurun D, et al. Atypical polymyalgia rheumatica as a presentation of metastatic cancer. Arch Intern Med. 1997; 157: 2381-2387.
26. Kane I, Menon S. Carcinoma of the prostate presenting as polymyalgia rheumatica. Rheumatology. 2003; 42: 385-387.
27. Kehler T, Ćurković B. Polymyalgia rheumatica and colon malignancy: case report. Clin Rheumatol. 2006; 25: 764-765.
28. Naschitz JE. Rheumatic syndromes: clues to occult neoplasia. Curr Opin Rheumatol. 2001; 13: 62-66.
29. Anton E. Polymyalgia rheumatica and malignancy: the question remains open. J Am Geriatr Soc. 2005; 53: 355-356.
30. Gonzáles-Gay MA, Garcia-Porrúa C, Calvarani C, et al. The spectrum of conditions mimicking polymyalgia rheumatica in northwestern Spain. J Rheumatol. 2000; 27: 2179-2184.
31. Dasgupta B, Matteson EL, Maradit-Kremers H. Management guidelines and outcome measures in polymyalgia rheumatica (PMR). Clin Exp Rheumatol. 2007; 25 (Suppl. 47): S139-S136.
32. Kyle V, Hazleman BL. Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months. Ann Rheum Dis. 1989; 48: 658-661.
33. Kremers HM, Reinalda MS, Crowson CS, et al. Relapse in a population based cohort of patients with polymyalgia rheumatica. J Rheumatol. 2005; 32: 65-73.
34. Salvarani C, Macchioni PL, Manzini C, et al. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica. A randomized trial. Ann Intern Med. 2007; 146: 631-639.
35. Ferracioli GF, Di Poi E, Damato R. Steroid sparing therapeutic approaches to polymyalgia rheumatica - giant cell arteritis. State of art and perspectives. Clin Exp Rheumatol. 2000; 18: 558-560.
36. Cimmino MA, Caporali R, Parodi M, et al. Initial prednisone treatment for polymyalgia rheumatica: is 12.5 mg enough? Ann Rheum Dis. 2007; 66 (Suppl. II): 77.
37. Luqmani R. Treatment of polymyalgia rheumatica and giant cell arteritis: are we any further forward? Ann Intern Med. 2007; 146: 674-676.
38. Caporali R, Cimmino MA, Ferraccioli G, et al. Prednisone plus methotrexate for polymyalgia rheumatica. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2004; 141: 493-500.
39. Stone JH. Methotrexate in polymyalgia rheumatica: kernel of truth or curse of Tantalus? Ann Intern Med. 2004; 141: 568-569.